GeNeuro

GeNeuro, NIH partner to develop novel antibody treatment for ALS

Friday, February 10, 2017

GeNeuro, a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, including multiple sclerosis (MS), has announced the signing of a Cooperative Research and Development Agreement (CRADA) with The National Institute of Neurological Disorders and Stroke (NINDS), part of the NIH, to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis (ALS). The research will evaluate the ability of these antibodies to neutralise a potential causal factor of ALS, the envelope protein of HERV-K (a family of Human Endogenous Retroviruses, HERVs). 

[Read More]

GeNeuro, Servier partner for multiple sclerosis

Wednesday, December 3, 2014

GeNeuro, a Switzerland-based developer of new therapies for neurology and autoimmune disorders, has entered into a strategic partnership with Servier, an independent French pharmaceutical company, to develop and market GNbAC1 in multiple sclerosis (MS). As the first drug addressing a causal factor of the disease, GNbAC1 has the potential to radically change the way MS patients are treated.

[Read More]